SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+9.29%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$392M
AUM Growth
+$392M
(+21%)
Cap. Flow
+$47M
Cap. Flow
% of AUM
12%
Top 10 Holdings %
Top 10 Hldgs %
39.92%
Holding
132
New
31
Increased
30
Reduced
24
Closed
25
Top Buys
| 1 |
Biogen
BIIB
|
$20.5M |
| 2 |
Novartis
NVS
|
$19M |
| 3 |
Pfizer
PFE
|
$13.3M |
| 4 |
SHPG
Shire pic
SHPG
|
$13.1M |
| 5 |
CELG
Celgene Corp
CELG
|
$8.71M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$13.8M |
| 2 |
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
|
$13M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$11.2M |
| 4 |
Merck
MRK
|
$9.85M |
| 5 |
AKAO
Achaogen, Inc.
AKAO
|
$7.93M |
Sector Composition
| 1 | Healthcare | 77.61% |
| 2 | Technology | 5.72% |
| 3 | Communication Services | 2.6% |
| 4 | Industrials | 2.35% |
| 5 | Consumer Discretionary | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
FibroGen
FGEN
$48.4M
| $4.09M | 0.8% |
165,700
+10,000
| +6% | +$247K |
|
|
GNCA
27
DELISTED
Genocea Biosciences, Inc.
GNCA
| $3.94M | 0.77% |
646,273
-50,000
| -7% | -$305K |
|
28
Charter Communications
CHTR
$35.7B
| $3.92M | 0.77% |
11,960
-4,205
| -26% | -$1.38M |
|
29
Travere Therapeutics
TVTX
$1.75B
| $3.86M | 0.75% |
209,131
+65,157
| +45% | +$1.2M |
|
|
CLLS
30
Cellectis
CLLS
$260M
| $3.83M | 0.75% |
+159,664
| New | +$3.83M |
|
31
Heron Therapeutics
HRTX
$204M
| $3.75M | 0.73% |
+250,000
| New | +$3.75M |
|
32
Alphabet (Google) Class A
GOOGL
$2.79T
| $3.69M | 0.72% |
4,346
-1,402
| -24% | -$1.19M |
|
33
Amicus Therapeutics
FOLD
$2.42B
| $3.57M | 0.7% |
500,000
-230,000
| -32% | -$1.64M |
|
|
SAGE
34
DELISTED
Sage Therapeutics
SAGE
| $3.55M | 0.69% |
50,000
-40,000
| -44% | -$2.84M |
|
|
ADMS
35
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $3.42M | 0.67% |
195,500
-74,500
| -28% | -$1.3M |
|
|
AVXS
36
DELISTED
AveXis, Inc. Common Stock
AVXS
| $3.42M | 0.67% |
45,000
| – | – |
|
37
Aldeyra Therapeutics
ALDX
$350M
| $3.34M | 0.65% |
668,500
+300,000
| +81% | +$1.5M |
|
|
LJPC
38
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $3.28M | 0.64% |
110,000
+59,323
| +117% | +$1.77M |
|
39
Cartesian Therapeutics
RNAC
$267M
| $3.27M | 0.64% |
228,534
-40,000
| -15% | -$573K |
|
40
Caesarstone
CSTE
$47.3M
| $3.26M | 0.64% |
+89,974
| New | +$3.26M |
|
|
DBVT
41
DBV Technologies
DBVT
$249M
| $3.18M | 0.62% |
90,167
+11,109
| +14% | +$391K |
|
42
Union Pacific
UNP
$132B
| $3.04M | 0.59% |
28,670
-7,406
| -21% | -$785K |
|
|
KITE
43
DELISTED
Kite Pharma, Inc.
KITE
| $2.75M | 0.54% |
35,000
-15,000
| -30% | -$1.18M |
|
44
Schlumberger
SLB
$52.2B
| $2.73M | 0.53% |
34,911
+550
| +2% | +$43K |
|
45
Starbucks
SBUX
$99.2B
| $2.72M | 0.53% |
46,631
+1,000
| +2% | +$58.4K |
|
|
PRTK
46
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.7M | 0.53% |
140,000
| – | – |
|
47
Snap-on
SNA
$16.8B
| $2.66M | 0.52% |
15,797
+4,825
| +44% | +$814K |
|
|
XLRN
48
DELISTED
Acceleron Pharma Inc.
XLRN
| $2.65M | 0.52% |
100,000
| – | – |
|
|
PVLA
49
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $2.6M | 0.51% |
1,000,000
+190,000
| +23% | +$494K |
|
50
CytomX Therapeutics
CTMX
$350M
| $2.59M | 0.51% |
+150,000
| New | +$2.59M |
|